Opportunities and challenges for the development of "core outcome sets" in neuro-oncology

Collapse authors list.
Millward, CP ORCID: 0000-0001-7727-1157, Armstrong, TS, Barrington, H ORCID: 0000-0001-9103-2670, Brodbelt, AR, Bulbeck, H, Byrne, A, Dirven, L ORCID: 0000-0001-9157-9895, Gamble, C ORCID: 0000-0002-3021-1955, Grundy, PL, Islim, AI et al (show 20 more authors) , Javadpour, M, Keshwara, SM, Krishna, ST, Mallucci, CL ORCID: 0000-0002-5509-0547, Marson, AG ORCID: 0000-0002-6861-8806, McDermott, MW, Meling, TR, Oliver, K, Pizer, B, Plaha, P, Preusser, M ORCID: 0000-0003-3541-2315, Santarius, T, Srikandarajah, N, Taphoorn, MJB, Watts, C, Weller, M ORCID: 0000-0002-1748-174X, Williamson, PR ORCID: 0000-0001-9802-6636, Zadeh, G ORCID: 0000-0002-6637-4502, Zamanipoor Najafabadi, AH and Jenkinson, MD ORCID: 0000-0003-4587-2139 (2022) Opportunities and challenges for the development of "core outcome sets" in neuro-oncology Neuro Oncology, 24 (7). pp. 1048-1055. ISSN 1522-8517, 1523-5866

Access the full-text of this item by clicking on the Open Access link.

Abstract

Core Outcome Sets (COS) define minimum outcomes to be measured and reported in clinical effectiveness trials for a particular health condition/health area. Despite recognition as critical to clinical research design for other health areas, none have been developed for neuro-oncology. COS development projects should carefully consider: scope (how the COS should be used), stakeholders involved in development (including patients as both research partners and participants), and consensus methodologies used (typically a Delphi survey and consensus meeting), as well as dissemination plans. Developing COS for neuro-oncology is potentially challenging due to extensive tumor subclassification (including molecular stratification), different symptoms related to anatomical tumor location, and variation in treatment options. Development of a COS specific to tumor subtype, in a specific location, for a particular intervention may be too narrow and would be unlikely to be used. Equally, a COS that is applicable across a wider area of neuro-oncology may be too broad and therefore lack specificity. This review describes why and how a COS may be developed, and discusses challenges for their development, specific to neuro-oncology. The COS under development are briefly described, including: adult glioma, incidental/untreated meningioma, meningioma requiring intervention, and adverse events from surgical intervention for pediatric brain tumors.

Item Type:	Article
Uncontrolled Keywords:	core outcome set, clinical trial, effectiveness, glioma, meningioma
Divisions:	Faculty of Health & Life Sciences Faculty of Health & Life Sciences > Inst. Systems, Molec & Integrative Biology > Inst. Systems, Molec & Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	04 May 2022 10:11
Last Modified:	01 Mar 2026 11:59
DOI:	10.1093/neuonc/noac062
Open Access URL:	https://doi.org/10.1093/neuonc/noac062
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3154268
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.